Tefibazumab: Difference between revisions
Content deleted Content added
added missing titles to ClinicalTrialsGov templates |
m Task 18 (cosmetic): eval 2 templates: del empty params (1×); |
||
| Line 46: | Line 46: | ||
'''Tefibazumab''' (named '''Aurexis''' but not approved) is a [[humanized monoclonal antibody]] for the treatment of severe infections with ''[[Staphylococcus aureus]]''. Possible indications include the treatment of ''S. aureus'' in a phase 2a patients with [[cystic fibrosis]]<ref>{{ClinicalTrialsGov|NCT00198289|Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs}}</ref> and of [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''S. aureus'']].<ref>{{cite journal | vauthors = Pan A, Lorenzotti S, Zoncada A | title = Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection | journal = Recent Patents on Anti-Infective Drug Discovery | volume = 3 | issue = 1 | pages = 10–33 | date = January 2008 | pmid = 18221183 | doi = 10.2174/157489108783413173 }}</ref> |
'''Tefibazumab''' (named '''Aurexis''' but not approved) is a [[humanized monoclonal antibody]] for the treatment of severe infections with ''[[Staphylococcus aureus]]''. Possible indications include the treatment of ''S. aureus'' in a phase 2a patients with [[cystic fibrosis]]<ref>{{ClinicalTrialsGov|NCT00198289|Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs}}</ref> and of [[methicillin-resistant Staphylococcus aureus|methicillin-resistant ''S. aureus'']].<ref>{{cite journal | vauthors = Pan A, Lorenzotti S, Zoncada A | title = Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection | journal = Recent Patents on Anti-Infective Drug Discovery | volume = 3 | issue = 1 | pages = 10–33 | date = January 2008 | pmid = 18221183 | doi = 10.2174/157489108783413173 }}</ref> |
||
It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal | vauthors = John JF | title = Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection | journal = Current Opinion in Molecular Therapeutics | volume = 8 | issue = 5 | pages = 455–60 | date = October 2006 | pmid = 17078388 |
It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal | vauthors = John JF | title = Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection | journal = Current Opinion in Molecular Therapeutics | volume = 8 | issue = 5 | pages = 455–60 | date = October 2006 | pmid = 17078388 }}</ref> |
||
== See also == |
== See also == |
||
Revision as of 19:51, 10 December 2020
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | Clumping factor A |
| Clinical data | |
| Trade names | Aurexis |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6548H10122N1730O2034S44 |
| Molar mass | 147035.72 g·mol−1 |
  (what is this?) (verify) | |
Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]
It was developed by Inhibitex.[3]
See also
- MSCRAMM (microbial surface components recognizing adhesive matrix molecules)
References
- ^ Clinical trial number NCT00198289 for "Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs" at ClinicalTrials.gov
- ^ Pan A, Lorenzotti S, Zoncada A (January 2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-Infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
- ^ John JF (October 2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Current Opinion in Molecular Therapeutics. 8 (5): 455–60. PMID 17078388.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |